Mersana Therapeutics, Inc. (NASDAQ:MRSN) director buys $47,232.00 worth of stock
Mersana Therapeutics, Inc. (NASDAQ: MRSN – Get a rating) Director Andrew AF Hack acquired 14,760 shares of the company in a transaction that took place on Thursday, June 2. The shares were purchased at an average cost of $3.20 per share, with a total value of $47,232.00. Following the completion of the acquisition, the administrator now owns 8,663,673 shares of the company, valued at approximately $27,723,753.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink.
Shares of Stock Mersana Therapeutics traded down $0.01 during Thursday’s trading, hitting $3.22. 726,636 shares of the company have been traded, compared to its average volume of 1,677,655. The company has a leverage ratio of 0.18, a current ratio of 4.28 and a quick ratio of 4.28. The company’s fifty-day moving average price is $3.75 and its 200-day moving average price is $4.83. Mersana Therapeutics, Inc. has a 12-month low of $2.68 and a 12-month high of $15.34. The company has a market capitalization of $312.31 million, a PE ratio of -1.29 and a beta of 2.38.
Mersana Therapeutic (NASDAQ: MRSN – Get a rating) last released its results on Monday, May 9. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.28). Mersana Therapeutics had a negative net margin of 8,826.73% and a negative return on equity of 119.10%. In the same quarter last year, the company achieved EPS of ($0.50). As a group, equity research analysts expect Mersana Therapeutics, Inc. to post year-to-date earnings per share of -2.13.
Several hedge funds and other institutional investors have recently changed their positions in the company. Royal Bank of Canada increased its stake in Mersana Therapeutics shares by 47.2% during the third quarter. Royal Bank of Canada now owns 6,941 shares of the company worth $66,000 after buying 2,226 more shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Mersana Therapeutics in the fourth quarter worth approximately $56,000. Point72 Hong Kong Ltd acquired a new position in shares of Mersana Therapeutics in the fourth quarter worth approximately $57,000. Quantbot Technologies LP acquired a new position in shares of Mersana Therapeutics in the first quarter valued at approximately $37,000. Finally, Victory Capital Management Inc. acquired a new position in Mersana Therapeutics stock in the first quarter valued at approximately $36,000. 92.74% of the shares are held by institutional investors.
Several research companies have published reports on MRSN. Zacks Investment Research downgraded Mersana Therapeutics shares from a “buy” rating to a “hold” rating in a Wednesday, May 11 research report. SVB Leerink cut its price target on Mersana Therapeutics shares from $25.00 to $16.00 and set an “outperform” rating on the stock in a Friday, Feb. 18 research report. HC Wainwright cut its price target on Mersana Therapeutics shares from $24.00 to $19.00 in a Monday, May 9 research report. Finally, Robert W. Baird cut his price target on Mersana Therapeutics shares from $23.00 to $18.00 in a Tuesday, May 10 research report. One equity research analyst gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat.com, Mersana Therapeutics has an average rating of “Buy” and an average target price of $17.80.
About Mersana Therapeutics (Get a rating)
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, is developing antibody-drug conjugates (ADCs) for cancer patients with unmet needs. It is developing XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in a Phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Get news and reviews for Mersana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Mersana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.